Literature DB >> 16127070

Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.

Peter J Petersen1, Patricia A Bradford.   

Abstract

In determining the quality control limits for the Clinical Laboratory Standards Institute-recommended quality control organisms with tigecycline, a number of inconsistencies in the results were encountered that appeared to be related to the age of the Mueller-Hinton broth II. This study was performed to examine the effect of medium age and supplementation with Oxyrase on the activity of tigecycline using a large number of clinical isolates.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16127070      PMCID： PMC1195416          DOI： 10.1128/AAC.49.9.3910-3918.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

2.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

5.  Effects of environmental factors on the in vitro potency of azithromycin.

Authors:  J A Retsema; L A Brennan; A E Girard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

6.  In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

Authors:  P J Petersen; N V Jacobus; W J Weiss; P E Sum; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

7.  Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

Authors:  S J Projan
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

8.  Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.

Authors:  Patricia A Bradford; Peter J Petersen; Mairead Young; C Hal Jones; Mark Tischler; John O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

9.  Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.

Authors:  T M Murphy; J M Deitz; P J Petersen; S M Mikels; W J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  Oxyrase, a method which avoids CO2 in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by CO2.

Authors:  S K Spangler; P C Appelbaum
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948
View more
  15 in total

1.  Effect of manganese in test media on in vitro susceptibility of Enterobacteriaceae and Acinetobacter baumannii to tigecycline.

Authors:  J Veenemans; J W Mouton; J A J W Kluytmans; R Donnely; C Verhulst; P H J van Keulen
Journal:  J Clin Microbiol       Date:  2012-06-20       Impact factor: 5.948

2.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest.

Authors:  Carlos Fernández-Mazarrasa; Olav Mazarrasa; Jorge Calvo; Asunción del Arco; Luis Martínez-Martínez
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

5.  Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC.

Authors:  M Torrico; N González; M J Giménez; L Alou; D Sevillano; D Navarro; M P Díaz-Antolín; N Larrosa; L Aguilar; N Garcia-Escribano
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

6.  Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.

Authors:  Ronald N Jones; Mary Jane Ferraro; L Barth Reller; Paul C Schreckenberger; Jana M Swenson; Helio S Sader
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

7.  Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

9.  Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus.

Authors:  Pierre Vaudaux; Bénédicte Fleury; Asllan Gjinovci; Elzbieta Huggler; Manuela Tangomo-Bento; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

10.  Validation and reproducibility assessment of tigecycline MIC determinations by Etest.

Authors:  Anne Bolmström; Asa Karlsson; Anette Engelhardt; Phion Ho; Peter J Petersen; Patricia A Bradford; C Hal Jones
Journal:  J Clin Microbiol       Date:  2007-05-23       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.